<DOC>
	<DOC>NCT00354445</DOC>
	<brief_summary>The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.</brief_summary>
	<brief_title>A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Subfoveal CNV secondary to AMD At least 1 but not more than 3 prior treatments for AMD Subfoveal scar or subfoveal atrophy Significant media opacities, including cataract, which might interfere with visual acuity</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Age-Related Macular Degeneration (AMD)</keyword>
	<keyword>pegaptanib sodium</keyword>
	<keyword>subfoveal CNV</keyword>
	<keyword>macugen</keyword>
</DOC>